Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | MGLL | Q99685 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036975 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2HTTLMNAMGLLL3MBTL1 | |
| SCHEMBL1038642 | 0.85 | MGLL (0.70) | SMN1; SMN2HTTLMNAMGLLPOLB | |
| SCHEMBL3042348 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2HTTLMNAMGLLL3MBTL1 | |
| SCHEMBL13489998 | 0.79 | SMN1; SMN2 (0.71) | SMN1; SMN2HTTLMNAMGLLPOLB | |
| SCHEMBL3038969 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2HTTLMNAMGLLPOLB | |
| SCHEMBL1036943 | 0.79 | MGLL (0.62) | SMN1; SMN2HTTLMNAMGLLPOLB | |
| SCHEMBL3032012 | 0.79 | SMN1; SMN2 (0.81) | SMN1; SMN2HTTLMNAMGLLPOLB | |
| SCHEMBL1037303 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2HTTLMNAMGLLPOLB | |
| SCHEMBL29754869 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTLMNAMGLLPOLB | |
| SCHEMBL3029076 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTLMNAMGLLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020150417-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | SMN1; SMN2 2644/4885HTT 3404/4885LMNA 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.